Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …

Molecular testing has become a mandatory component of the non-small cell lung cancer
(NSCLC) management. The detection of EGFR, BRAF and MET mutations as well as the …

Colorectal cancer (CRC) is among the most lethal and prevalent malignancies in the world
and was responsible for nearly 881,000 cancer-related deaths in 2018. Surgery and …

Paclitaxel (PTX)-based chemotherapy remains the main approach to treating lung cancer
but systemic toxicity limits its use. As chimeric antigen receptor-T (CAR-T) cell-derived …

Cancer immunotherapy (CIT) with antibodies targeting the programmed cell death 1 protein
(PD-1)/programmed cell death 1 ligand 1 (PD-L1) axis have changed the standard of care in …

Targeting nucleotide metabolism can not only inhibit tumor initiation and progression but
also exert serious side effects. With in-depth studies of nucleotide metabolism, our …

Introduction Dabrafenib plus trametinib was found to have robust antitumor activity in
patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC). We report updated …

The treatment paradigm for patients with advanced non–small cell lung cancer has
substantially changed with the discovery of immunotherapy. The incorporation of …

Predicting the clinical response to chemotherapeutic or targeted treatment in patients with
locally advanced or metastatic lung cancer requires an accurate and affordable tool. Tumor …

Lung cancer is one of the most common cancers and has a high mortality rate. Due to its
high incidence, the clinical management of the disease remains a major challenge. Several …